PATHOGENESIS AND MANAGEMENT OF BONE LESIONS IN MULTIPLE MYELOMA
- 1 April 1997
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 11 (2) , 349-361
- https://doi.org/10.1016/s0889-8588(05)70435-4
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myelomaBone, 1994
- Lack of IL‐1 secretion from human myeloma cells highly purified by immunomagnetic separationBritish Journal of Haematology, 1993
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992
- Treatment of bone metastases from breast cancer and myeloma with pamidronateEuropean Journal of Cancer and Clinical Oncology, 1991
- Use of pamidronate for multiple myeloma osteolytic lesionsThe Lancet, 1990
- LONG-TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPYHematological Oncology, 1990
- The biology of interleukin 1 and comparison to tumor necrosis factorImmunology Letters, 1987
- Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma CellsNew England Journal of Medicine, 1987
- Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple MyelomaMetabolic Bone Disease and Related Research, 1982
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980